Trial · NCT01104415
Results by group21
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 21
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Drug-Related TEAEs in the Core Phase | Telotristat Etiprate- Core Phase | Any TEAE | 15 | Participants | |
| Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Drug-Related TEAEs in the Core Phase | Telotristat Etiprate- Core Phase | Drug-Related TEAE | 5 | Participants | |
| Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Drug-Related TEAEs in the Extension Period | Telotristat Etiprate- Extension Period | Any TEAE | 11 | Participants | |
| Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Drug-Related TEAEs in the Extension Period | Telotristat Etiprate- Extension Period | Drug-Related TEAE | 4 | Participants | |
| Change From Baseline in Number of Bowel Movements (BMs) | Telotristat Etiprate- Core Phase | -2.60 | Standard Deviation 1.381 | number of bowel movements/day | |
| Change From Baseline in Number of Bowel Movements (BMs) | Telotristat Etiprate- Extension Period | -2.85 | Standard Deviation 1.64 | number of bowel movements/day | |
| Change From Baseline in Stool Form/Consistency | Telotristat Etiprate- Core Phase | -0.79 | Standard Deviation 0.707 | score on a scale | |
| Change From Baseline in Stool Form/Consistency | Telotristat Etiprate- Extension Period | -1.31 | Standard Deviation 0.666 | score on a scale | |
| Change From Baseline in Percentage of Days With Sensation of Urgency to Defecate | Telotristat Etiprate- Core Phase | -11.32 | Standard Deviation 36.660 | percentage of days | |
| Change From Baseline in Percentage of Days With Sensation of Urgency to Defecate | Telotristat Etiprate- Extension Period | -22.79 | Standard Deviation 49.546 | percentage of days | |
| Change From Baseline in Sensation/Severity of Nausea Using 100 mm Visual Analog Scale (VAS) | Telotristat Etiprate- Core Phase | -2.43 | Standard Deviation 5.208 | score on a scale | |
| Change From Baseline in Sensation/Severity of Nausea Using 100 mm Visual Analog Scale (VAS) | Telotristat Etiprate- Extension Period | -5.71 | Standard Deviation 8.797 | score on a scale | |
| Number of Participants With an Improvement in Global Assessment of Symptoms Associated With Carcinoid Syndrome | Telotristat Etiprate- Core Phase | 10 | Participants | ||
| Number of Participants With an Improvement in Global Assessment of Symptoms Associated With Carcinoid Syndrome | Telotristat Etiprate- Extension Period | 4 | Participants | ||
| Change From Baseline in Daily Severity of Abdominal Pain or Discomfort Using 100 mm Visual Analog Scale (VAS) | Telotristat Etiprate- Core Phase | -8.66 | Standard Deviation 18.724 | score on a scale | |
| Change From Baseline in Daily Severity of Abdominal Pain or Discomfort Using 100 mm Visual Analog Scale (VAS) | Telotristat Etiprate- Extension Period | -24.11 | Standard Deviation 19.643 | score on a scale | |
| Change From Baseline in Daily Number of Cutaneous Flushing Episodes | Telotristat Etiprate- Core Phase | -0.88 | Standard Deviation 1.205 | Daily number of flushing episodes | |
| Change From Baseline in Daily Number of Cutaneous Flushing Episodes | Telotristat Etiprate- Extension Period | -1.55 | Standard Deviation 1.784 | Daily number of flushing episodes | |
| Number of Participants Achieving Clinically Meaningful Symptom Reduction in the Core Phase | Telotristat Etiprate- Core Phase | 14 | Participants | ||
| Change From Baseline in Urinary 5-Hydroxyindoleacetic Acid (HIAA) Levels | Telotristat Etiprate- Core Phase | -97.26 | Standard Deviation 164.995 | mg/24 hours |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01104415/results